Celularity Inc. revenue by segment CELU

Annual Quarterly

Celularity Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Degenerative Disease at $3.4 million, 63% of the total. By sales mix, the largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $4.1 million, 75% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jun 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Revenue	19	5	4	4	5	6	11	18	9
Operating segments
Degenerative Disease	9 -75.0% share 50.4%	3 -7.1% share 63.3%	2 -78.4% share 54.7%	2 -90.0% share 39.3%	2 -72.0% share 42.5%	4 share 64.5%	10 share 85.4%	16 share 89.1%	8 share 86.1%
Cell Therapy	5 share 24.7%	1 +76.4% share 24.7%	0 +86.7% share 12.8%	1 share 29.0%	2 share 30.1%	1 share 13.2%	0 share 2.3%	—	—
Biobanking	5 -11.5% share 24.9%	1 -48.9% share 12.0%	1 -11.2% share 32.5%	1 +1.4% share 31.7%	1 +12.1% share 27.4%	1 share 22.2%	1 share 12.3%	1 share 7.1%	1 share 13.9%
Sales mix
Product	7 -72.0% share 35.9%	4 +70.7% share 74.8%	1 -90.4% share 22.5%	1 -90.3% share 21.5%	1 -73.7% share 16.9%	2 share 41.5%	9 share 78.9%	9 share 50.4%	3 share 36.5%
License Royalty And Other	7 -52.5% share 39.2%	1 -65.5% share 13.2%	2 +73.0% share 45.0%	2 -75.1% share 46.8%	3 -36.2% share 55.7%	2 share 36.3%	1 share 8.8%	8 share 42.5%	5 share 49.6%
Services	5 -11.5% share 24.9%	1 -48.9% share 12.0%	1 -11.2% share 32.5%	1 +1.4% share 31.7%	1 +12.1% share 27.4%	1 share 22.2%	1 share 12.3%	1 share 7.1%	1 share 13.9%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CELU (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Florham Park, NJ
SEC filer status: , Emerging growth company
SEC CIK: 1752828
Former names: GX Acquisition Corp. (until Jul 19, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.